Por: The Boston Globe Business July 25, 2023
Biogen said Tuesday that it plans to cut about 1,000 jobs, roughly 11 percent of its global workforce, to lower costs as the Cambridge-based biotech begins to roll out the new Alzheimer’s drug it co-developed and prepares for possible approval of another drug, for depression, next week.Biogen, which had 8,725 employees worldwide at the end of next year, didn’t specify in its second-quarter earnings call where the cuts will take place but... + full article
The Boston Globe USA Business June 13, 2023
This is an excerpt of an article from STAT, the health and medicine news site that’s a partner to the Globe. For a full version of this story and related coverage, .Biogen, a biotech giant plagued by years of boardroom strife, said late Monday that the longtime and polarizing... + más
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Fox Business USA Business December 30, 2022
Check out what's clicking on FoxBusiness.com A report by two House committees questioned the approval process for an Alzheimer’s drug produced by Biogen. Congressional investigators called the process rife with irregularities.The drug in question is Aduhelm, which was... + más
BioVie president and CEO Cuong Do discusses the positive results of its Parkinson's and Alzheimer's phase 2 trials and explains how its NE3107 drug could reverse the biological clock on 'Varney & Co.' An 18-month-long investigation conducted by the House... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
Probe: Alzheimer's drug approval 'rife with irregularities' | 10 WBNS
Los Angeles Times USA Science December 30, 2022
The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
Fox Business USA Business September 28, 2022
Dr. Stephen O'Brien, chief medical officer of Mediflix, shares how his streaming platform is trailblazing access to medical information for everyone. Shares of Biogen surged Wednesday's following news that its drug lecanemab showed promising signs of potentially... + más
Biogen shares rally as Alzheimer's drug results show promise | CBS News
Alzheimer's drug shows promise in early results of study | WPLG Local 10
Fox Business USA Business September 27, 2022
Aflac Chairman and CEO Dan Amos says record-high inflation poses a ‘challenging environment’ for consumers. Biogen has to settle allegations that it paid kickbacks to persuade doctors to prescribe its multiple sclerosis drugs. The settlement comes after former Biogen... + más
Biogen to pay $900m to settle whistle-blower suit over kickbacks | The Boston Globe
About iurex | Privacy Policy | Disclaimer |